Physician profile
Charmin Broughton
NPI 1144634734
$11,436.13
in general payments reported to CMS, 2019-2025
33 companies · $4,178 in 2025
The $4,178 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,436 · 2023: $2,759 · 2024: $2,165 · 2025: $4,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,305 · Travel and Lodging: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,304.50 |
| Travel and Lodging | $1,798.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,501.72 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $1,867.23 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $1,348.01 | 2021-2025 | |
| Lundbeck LLC | $740.73 | 2021-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $599.93 | 2021-2025 | Xtampza, Belbuca, Nucynta |
| Relievant Medsystems, INC. | $548.92 | 2023 | Intracept |
| Scilex Pharmaceuticals INC. | $453.24 | 2022-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.67 | 2023-2025 | Relistor |
| Pfizer INC. | $429.21 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $405.67 | 2021 | |
| Painteq LLC | $242.24 | 2023-2024 | Painteq |
| Lilly USA, LLC | $197.67 | 2022-2025 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $187.76 | 2022 | |
| Radius Health, INC. | $182.87 | 2023-2025 | Tymlos |
| Mml US, INC. | $177.49 | 2022-2023 | Reactiv8 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $157.64 | 2023-2025 | Qutenza |
| Si-Bone, INC. | $148.83 | 2024-2025 | |
| Vertos Medical, INC. | $138.10 | 2023 | Mild Device Kit |
| Amgen INC. | $93.42 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $88.82 | 2024-2025 | |
| Ibsa Pharma INC. | $80.71 | 2022-2025 | Tirosint, Licart, Flector |
| Grt US Holding, INC. | $64.17 | 2022 | |
| Tonix Medicines, INC. | $61.46 | 2025 | Tonmya |
| Spinal Simplicity, LLC | $47.48 | 2022-2023 | Ha Minuteman G3-R |
| Upsher-Smith Laboratories LLC | $44.87 | 2022 | |
| Medtronic, INC. | $43.30 | 2022-2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $41.57 | 2025 | Symbravo |
| Bioventus LLC | $31.13 | 2022-2025 | Xcell |
| Spr Therapeutics, INC | $23.80 | 2024 | Sprint Pns System |
| Merck Sharp & Dohme LLC | $16.39 | 2022 | |
| Abbott Laboratories | $15.74 | 2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $13.50 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmin Broughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.